SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
InterMune (nasdaq)ITMN
An SI Board Since March 2000
Posts SubjectMarks Bans Symbol
508 36 0 ITMN
Emcee:  Secret_Agent_Man Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
233Jim, Many thanks for graciously sharing your cc summary. One clarification: rkrw-4/30/2002
232This morning I read through their most recent 10K and was surprised to read manapchristi12534-4/29/2002
231330 patient, double blind placebo controlled study.rkrw-4/26/2002
230Hi Dave, They are doing a PIII for IPF that will finish in August and data is dIRWIN JAMES FRANKEL-4/26/2002
229I am looking at a slide from a recent presentation (BoA?), it shows <i>unakeokalani'nui-4/26/2002
228<Actimmune for IPF> is the trial double blinded? Thanks again, DavidElmer-4/26/2002
227A couple have asked about the NEJM study. Here is the ATS monograph in which thIRWIN JAMES FRANKEL-4/26/2002
226Wilder, "Now make it go up, please." Thanks for making me laugh. ThIRWIN JAMES FRANKEL-4/26/2002
225IJ, I believe you just set the standard for quality in digesting a CC. I didn&keokalani'nui-4/26/2002
224ITMN CC 4/24/02 This summary is organized logically rather than in the order IRWIN JAMES FRANKEL-4/25/2002
223Short interest up 5% Apr 15 - 5,783,677 Mar 15 - 5,533,157 1,076,420 avg dailIRWIN JAMES FRANKEL-4/25/2002
222Briefing.com's summary was slightly ahead of consensus estimates for earningCzechsinthemail-4/24/2002
221A couple of points from the CC: - Actimunne sales grew 28% sequential (1Q over IRWIN JAMES FRANKEL-4/24/2002
220investor.intermune.com snip BRISBANE, Calif., Apr 24, 2002 /PRNewswire-FirstCaquidditch-4/24/2002
219I just bought back 1/2 my position. Hope we are right. I really doubt if pulmokeokalani'nui-4/24/2002
218Looks like some exiting for the sidelines ahead of the earnings report. ITMN haCzechsinthemail-4/24/2002
217Hi Dave, If there was a substantial acceleration in Actimunne sales it would liIRWIN JAMES FRANKEL-4/23/2002
216If revenue from Actimmune exceeds expectation by a lot tomorrow, would you read Elmer-4/23/2002
215Friday April 19, 5:03 pm Eastern Time Press Release SOURCE: InterMune, Inc. InteIRWIN JAMES FRANKEL-4/19/2002
214The Fibrogen (private) Mab is likely a medx Mab. A 10k-wiz search among edgar-rkeokalani'nui-4/16/2002
213ITMN's licensing of a second IPF compound could also be seen as a response ttuck-4/15/2002
212ITMN is co-developing this with molichem. No mention of itmn in the pr. Thurrkrw-4/12/2002
211Wednesday April 10, 7:00 am Eastern Time Press Release SOURCE: InterMune, Inc. IIRWIN JAMES FRANKEL-4/10/2002
210IJ, "...negative interpretation from some RMC investigators who had reviewequidditch-4/8/2002
209<Seems as though the Rochester Mayo Clinic hasn't found anything it likesIRWIN JAMES FRANKEL-4/8/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News